Loading organizations...
§ Private Profile · San Francisco, CA, USA
AI software platform automating clinical trial document creation and data management for pharmaceutical and biotech companies.
Baseline AI has raised $500K across 1 funding round.
Key people at Baseline AI.
Baseline AI was founded in 2023 by Zoe Sheill (Founder) and Nabil Baugher (Founder).
Baseline AI has raised $500K in total across 1 funding round.
Baseline AI is a San Francisco, California-based software company that provides artificial intelligence automation for clinical trial document creation and data management. The business-to-business platform serves pharmaceutical and biotechnology organizations by streamlining the complex generation of study protocols, investigator brochures, data collection forms, and clinical databases. Operating with a lean team of just two employees, the enterprise software aims to reduce extensive manual administrative work. This automation targets inefficiencies that can cost up to $27 million in direct expenses and lost revenue for a single phase three clinical research trial. The early-stage software startup is currently backed by the prominent accelerator Y Combinator and leverages previous engineering and machine learning experience from major technology companies including YouTube, Slack, and SpaceX. Baseline AI was officially founded in 2023 by co-founders Nabil Baugher and Zoe Sheill.
Key people at Baseline AI.
Baseline AI was founded in 2023 by Zoe Sheill (Founder) and Nabil Baugher (Founder).
Baseline AI has raised $500K in total across 1 funding round.
Baseline AI's investors include Pareto Holdings, Y Combinator.
Baseline AI has raised $500K across 1 funding round. Most recently, it raised $500K Seed in September 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2024 | $500K Seed | — | Pareto Holdings, Y Combinator | Announced |
Baseline AI is a San Francisco-based startup revolutionizing clinical trial data management by leveraging artificial intelligence to automate document creation, database modeling, and data transformation processes. The company’s platform is purpose-built for pharmaceutical, biotech, and clinical research organizations, enabling them to drastically reduce the time and cost associated with launching and running clinical trials. By automating traditionally manual workflows—such as generating case report forms (CRFs), building databases, and creating analysis code—Baseline AI helps clients avoid costly delays and errors, accelerating the path to bringing new treatments to market. Since its founding in 2023, the company has rapidly gained traction, securing a convertible note round of $500K and participating in Y Combinator’s S24 batch, signaling strong early momentum and investor interest.
Baseline AI was co-founded in 2023 by Nabil Baugher and Zoe Sheill, both MIT graduates with backgrounds in computation, cognition, and experience at leading tech companies like SpaceX, Google, and Slack. The idea emerged from their shared frustration with the inefficiencies in clinical trial processes, particularly the slow, manual, and error-prone nature of data management. Zoe’s personal experience participating in a clinical trial further highlighted the need for innovation in the space. The founders recognized that while drug discovery was advancing rapidly, the clinical trial process remained a bottleneck. Their solution—automating the creation of study documents and data management workflows—quickly gained validation, leading to early adoption by industry partners and acceptance into Y Combinator, where they showcased their technology to a global audience.
Baseline AI is riding the wave of AI-driven automation in healthcare, a sector that has long been ripe for digital transformation. The timing is critical: as pharmaceutical and biotech companies face increasing pressure to accelerate drug development and reduce costs, AI-powered solutions like Baseline AI are becoming essential. The company is part of a broader trend where startups are applying AI to solve complex, domain-specific problems, moving beyond general-purpose AI to deliver targeted, high-impact solutions. By streamlining clinical trial workflows, Baseline AI not only improves efficiency but also helps bring life-saving treatments to patients faster, influencing the broader ecosystem by setting a new standard for data management in clinical research.
Baseline AI is poised to become a key player in the AI-driven transformation of clinical trials. As the company scales its technology to support larger and more complex trials, its impact on the industry is likely to grow. The future will see increased adoption by pharmaceutical and biotech firms, as well as potential expansion into adjacent areas like regulatory compliance and real-world evidence. The convergence of AI, healthcare, and regulatory innovation will continue to shape Baseline AI’s journey, making it a company to watch in the evolving landscape of clinical research. Just as Y Combinator’s Demo Day highlighted the dominance of AI startups, Baseline AI stands out as a prime example of how targeted AI solutions can drive meaningful change in critical industries.
